- Home
- CELU vs RAPT Comparison
CELU vs RAPT Comparison
Compare CELU & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELU
- RAPT
- Stock Information
- Founded
- CELU 2016
- RAPT 2015
- Country
- CELU United States
- RAPT United States
- Employees
- CELU N/A
- RAPT N/A
- Industry
- CELU Biotechnology: Pharmaceutical Preparations
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- CELU Health Care
- RAPT Health Care
- Exchange
- CELU Nasdaq
- RAPT Nasdaq
- Market Cap
- CELU 50.4M
- RAPT 59.1M
- IPO Year
- CELU N/A
- RAPT 2019
- Fundamental
- Price
- CELU $2.30
- RAPT $1.20
- Analyst Decision
- CELU
- RAPT Hold
- Analyst Count
- CELU 0
- RAPT 10
- Target Price
- CELU N/A
- RAPT $6.00
- AVG Volume (30 Days)
- CELU 89.6K
- RAPT 9.1M
- Earning Date
- CELU 12-06-2024
- RAPT 03-06-2025
- Dividend Yield
- CELU N/A
- RAPT N/A
- EPS Growth
- CELU N/A
- RAPT N/A
- EPS
- CELU N/A
- RAPT N/A
- Revenue
- CELU $48,200,000.00
- RAPT N/A
- Revenue This Year
- CELU N/A
- RAPT N/A
- Revenue Next Year
- CELU $233.89
- RAPT N/A
- P/E Ratio
- CELU N/A
- RAPT N/A
- Revenue Growth
- CELU 225.94
- RAPT N/A
- 52 Week Low
- CELU $1.30
- RAPT $0.79
- 52 Week High
- CELU $7.97
- RAPT $27.35
- Technical
- Relative Strength Index (RSI)
- CELU 52.94
- RAPT 43.92
- Support Level
- CELU $2.04
- RAPT $1.07
- Resistance Level
- CELU $2.39
- RAPT $1.29
- Average True Range (ATR)
- CELU 0.17
- RAPT 0.17
- MACD
- CELU 0.02
- RAPT -0.04
- Stochastic Oscillator
- CELU 70.76
- RAPT 15.43
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.